Citation

Gurm HS, Hoogwerf B. Cleve. Clin. J. Med. 2003; 70(11): 991-997.

Copyright

(Copyright © 2003, Cleveland Clinic Educational Foundation)

DOI

10.3949/ccjm.70.11.991

PMID

14650474

Abstract

The landmark Heart Protection Study (Lancet 2002; 360:7-22) found benefit in treating subjects at high risk of a coronary event with simvastatin 40 mg daily, regardless of baseline low-density lipoprotein cholesterol level and in all subgroups, including women and the elderly. The study found no benefit of simvastatin therapy in preventing noncardiac events (eg, dementia, osteoporotic fractures), and no negative effects, such as an increase in cancer, respiratory disease, or suicide.

Language: en

Keywords

Cholesterol, HDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Treatment Outcome